Loeb S and Partin AW. “Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.” Reviews in Urology, Fall 2008; 10: 304. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/
Loeb S and Partin AW. “Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.” Reviews in Urology, Fall 2008; 10: 304. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/
Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ. “Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.” Journal of Urology, June 2008; 179: 2197. Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739
Loeb S and Catalona WJ. “Counterpoint: the case for active treatment.” Journal of the National Comprehensive Cancer Network, August 2007; 5: 699. Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174
Loeb S and Catalona WJ. “Early versus delayed intervention for prostate cancer: the case for early intervention.” Nature Clinical Practice Urology, July 2007; 4: 348. Link: http://www.ncbi.nlm.nih.gov/pubmed/17563779
Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ. “Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.” Urologic Oncology: Seminars and Original Investigations 2006; 24: 465. Link: http://www.ncbi.nlm.nih.gov/pubmed/17138126
Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ. “Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression” Urology, 2006; 68: 99. Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410
Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ. “Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening” Journal of Urology 2006; 175: 902. Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576
Roehl KA, Loeb S, Antefnor JA, Corbin N, and Catalona WJ. “Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.” Journal of Urology, December 2006; 176: 2438. Link: http://www.ncbi.nlm.nih.gov/pubmed/17085123
Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB. “Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age” Urology, February 2006; 67: 316. Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597 In the general US population, the median PSA level is… Read More